You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

June 19, 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

PCSK-9 inhibitors achieve next milestone, plus 4 more FDA actions

An FDA panel recommends approving 2 cholesterol-lowering PCSK-9 inhibitors. » More FDA actions

Acid-reducing meds up risk of C diff infection in kids: Study

Infants and children who are given prescription acid-reducing medications face a substantially higher risk of developing Clostridium difficile infection, according to a new study.
» Study details

Continuing Education

MTM essentials for COPD management: Part 1

This month’s CE activity is part of a CPE series, Medication Therapy Management for the Patient with Respiratory Disease. From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month’s activity is to assist pharmacists in understanding the pathophysiology and pharmacologic treatment of COPD and to discuss how COPD is similar to and different from other chronic respiratory disorders.

To read and print the article with TEST QUESTIONS, click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT31-KTJ28.


Announcement: The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. To review your registration page or to register, go to: https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Edoxaban: An oral inhibitor of factor Xa

A review to help guide clinicians on edoxaban's (Savaysa's) use and place in therapy. Edoxaban is a once-daily oral selective reversible inhibitor of factor Xa approved by FDA for reduction of stroke risk and systemic embolism in nonvalvular atrial fibrillation (NVAF) and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
» Safety and efficacy details

 

RELATED ARTICLES

5 things to know about cholesterol-lowering PCSK9 inhibitors

Heartburn drugs linked to heart attacks

RESOURCES

Latest Clinical News

Powered by Modern Medicine UBM  logo

UBM MEDICA